Vis enkel innførsel

dc.contributor.authorAarhus, Thomas Ihle
dc.contributor.authorBjørnstad, Frithjof Andreas
dc.contributor.authorWolowczyk, Camilla Izabel
dc.contributor.authorLarsen, Kristin Uhlving
dc.contributor.authorRognstad, Line
dc.contributor.authorLeithaug, Trygve
dc.contributor.authorUnger, Anke
dc.contributor.authorHabenberger, Peter
dc.contributor.authorWolf, Alexander
dc.contributor.authorBjørkøy, Geir
dc.contributor.authorPridans, Clare
dc.contributor.authorEickhoff, Jan
dc.contributor.authorKlebl, Bert
dc.contributor.authorHoff, Bård Helge
dc.contributor.authorSundby, Eirik
dc.date.accessioned2023-12-14T08:18:39Z
dc.date.available2023-12-14T08:18:39Z
dc.date.created2023-06-12T09:36:14Z
dc.date.issued2023
dc.identifier.citationJournal of Medicinal Chemistry. 2023, 66 (10), 6959-6980.en_US
dc.identifier.issn0022-2623
dc.identifier.urihttps://hdl.handle.net/11250/3107494
dc.description.abstractColony-stimulating factor-1 receptor (CSF1R) is a receptor tyrosine kinase that controls the differentiation and maintenance of most tissue-resident macrophages, and the inhibition of CSF1R has been suggested as a possible therapy for a range of human disorders. Herein, we present the synthesis, development, and structure–activity relationship of a series of highly selective pyrrolo[2,3-d]pyrimidines, showing subnanomolar enzymatic inhibition of this receptor and with excellent selectivity toward other kinases in the platelet-derived growth factor receptor (PDGFR) family. The crystal structure of the protein and 23 revealed that the binding conformation of the protein is DFG-out-like. The most promising compounds in this series were profiled for cellular potency and subjected to pharmacokinetic profiling and in vivo stability, indicating that this compound class could be relevant in a potential disease setting. Additionally, these compounds inhibited primarily the autoinhibited form of the receptor, contrasting the behavior of pexidartinib, which could explain the exquisite selectivity of these structures.en_US
dc.language.isoengen_US
dc.publisherACS Publicationsen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleSynthesis and Development of Highly Selective Pyrrolo[2,3-d]pyrimidine CSF1R Inhibitors Targeting the Autoinhibited Formen_US
dc.title.alternativeSynthesis and Development of Highly Selective Pyrrolo[2,3-d]pyrimidine CSF1R Inhibitors Targeting the Autoinhibited Formen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.source.pagenumber6959-6980en_US
dc.source.volume66en_US
dc.source.journalJournal of Medicinal Chemistryen_US
dc.source.issue10en_US
dc.identifier.doi10.1021/acs.jmedchem.3c00428
dc.identifier.cristin2153607
dc.relation.projectNorges forskningsråd: 223255en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode2


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal